Even Robert Langer has experienced rejection and doubters. But as Langer’s story repeatedly shows, a good idea will eventually be recognized. During the 2022 Elsevier Distinguished Lecture on April 18 ...

Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of ...

Decoy Therapeutics announces that Massachusetts Institute of Technology, MIT, Professor and Moderna co-founder Robert Langer, ScD will join the ...

Robert Langer has spent more than 30 years working with biomaterials and has seen their development from simple implants to complex multifunctional interfaces with the body. He shares his vision ...

With a background in engineering, why did you decide to move into the world of drug delivery? After my doctorate, I was not sure what I wanted to do. Most of my fellow graduates took jobs in oil ...

She went on to do post doctoral research with Dr. Robert Langer at MIT, Boston, investigating controlled drug delivery. Subsequently, after a three-year taste of industry at the Glaxo Smith Kline ...

Professor and Moderna co-founder Robert S. Langer, ScD will join the company’s Scientific Advisory Board (SAB) upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals ...